- © 2009 by American Society of Clinical Oncology
ERRATA
The April 20, 2009, article by Sargent et al, entitled, “Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer” (J Clin Oncol 27:1948–1955, 2009), contained errors in some of the data given for PFS and OS.
In the Results section, under Experimental Versus Control Arms, the third and fifth sentences were given as:
“For PFS, the experimental treatment provided a benefit in both PS 0 to 1 patients (HR = 0.81 for experimental v control treatment; 95% CI, 0.77 to 0.86; P < .00001; median PFS, 17.9 months for experimental treatment v 16.4 months for control) and PS2 patients (HR = 0.79 for experimental v control treatment; 95% CI, 0.66 to 0.96; P = .02; median PFS, 8.8 months for experimental treatment v 8.2 months for control).”
“Similarly, for the OS end point, the experimental treatment provided similar benefit in both PS 0 to 1 patients (HR = 0.87; 95% CI, 0.82 to 0.93; P < .00001; median OS, 8.4 months for experimental treatment v 6.7 months for control) and PS2 patients (HR = 0.88; 95% CI, 0.73 to 1.07; P = .21; median OS, 6.0 months for experimental treatment v 4.0 months for control).”
While they should have been:
“For PFS, the experimental treatment provided a benefit in both PS 0 to 1 patients (HR = 0.81 for experimental v control treatment; 95% CI, 0.77 to 0.86; P < .00001; median PFS, 8.4 months for experimental treatment v 6.7 months for control) and PS2 patients (HR = 0.79 for experimental v control treatment; 95% CI, 0.66 to 0.96; P = .02; median PFS, 6.0 months for experimental treatment v 4.0 months for control).”
“Similarly, for the OS end point, the experimental treatment provided similar benefit in both PS 0 to 1 patients (HR = 0.87; 95% CI, 0.82 to 0.93; P < .00001; median OS, 17.9 months for experimental treatment v 16.4 months for control) and PS2 patients (HR = 0.88; 95% CI, 0.73 to 1.07; P = .21; median OS, 8.8 months for experimental treatment v 8.2 months for control).”
